Analog DevicesEVAL-ADM2763EEBZDevelopment Kits and Tools
ADM2763E Bus Line Transceiver Evaluation Board
The ADM2761/2763E isolated RS485 includes smart features to reduce end system install & debug time. Future-proofs your network bandwidth. ADM3058E enables backwards compatibility & can fully isolate higher bandwidth CAN FD networks over longer distances and improved timing margins.
- ADM3058E (flagship): isoCAN
- ADM2761E: Half Duplex iso RS-485
- ADM2763E: Full Duplex iso RS-485
1500VDCIsolated Transceivers for Solar Energy and HV Batteries:
- • Protocol options for CAN FD or RS-485
- • 5.7kV reinforced iCoupler digital isolation & IEC ESD for signal integrity in harsh environments
- • CISPR32 Class B emissions on a 2-layer PCB reduces design complexity and time-to-market
Key Features and Benefits
- • 1500V higher-voltage systems have reduced installation times and enables a significant reduction in system costs as well as the optimization of annual solar energy production.
- • IEC 61000-4-2 ESD and 5.7kV reinforced iCoupler digital isolation with > 8mm creepage and clearance. Maintain signal integrity in the harsh environments with the trusted safety of iCoupler digital isolation.
- • Passes EN 55032/CISPR 32 Class B emissions on a 2 layer board. Enables a robust IEC61000-4-2 node with CISPR32 rated emissions on a 2-layer board while reducing design complexity, component and board cost and time-to-market.
Applications
- • Energy: Solar
- • Industrial Automation
- • Building Infrastructure: Building Control and Automation
Block Diagrams and Tables
Related Evaluation Board
EVAL-ADM3058EEBZ
EVAL-ADM2761EEBZ
EVAL-ADM2763EEBZ
ADM3058EBRIZ
ADM3058EBRIZ-RL
ADM2761EBRWZ
ADM2761EBRWZ-RL7
ADM2763EBRWZ
ADM2763EBRWZ-RL7
EVAL-ADM3058EEBZ
| Compliant | |
| EAR99 | |
| Active | |
| 8543.70.98.60 | |
| Automotive | No |
| PPAP | No |
| Evaluation Board | |
| Interface Tools | |
| ADM2763E | |
| Bus Line Transceiver |
Design AI-powered medical devices
Explore system design tips, part recs and AI insights to help you build faster, safer diagnostic and therapy solutions—all in Arrow’s latest white paper.

